These findings underscore the potential of benzimidazole–Schiff-base scaffolds as AChE and BuChE inhibitors, holding potential for advancing innovative treatments for Alzheimer’s disease. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.